SAN DIEGO, CA December 1, 2009/MarketWire/– Aegis Therapeutics LLC (Aegis) announced today that they have signed a License Agreement providing Roche access to Aegis’ proprietary ProTek® stabilization technology. The ProTek® technology covers the use of specific excipients as stabilizers in certain manufacturing processes and formulations of protein-based therapeutics.
Under the terms of the agreement, Aegis will receive undisclosed up-front licensing fees and individual product-related event and royalty payments.
Edward T. Maggio, PhD, Chief Executive Officer of Aegis said, “We are pleased to be working with Roche, an innovative world leader in monoclonal antibody and peptide based therapeutics. We view this agreement as a significant validation of our proprietary ProTek® peptide and protein stabilization technology.”
About Aegis Therapeutics
Aegis Therapeutics LLC is a drug delivery technology company commercializing its patented drug delivery and drug formulation technologies through product-specific licenses. Our patented Intravail® drug delivery technology enables the non-invasive delivery of a broad range of protein, peptide and non-peptide macromolecular and small molecule therapeutics via the intranasal administration route with exceptionally high and unmatched bioavailability that can currently only be achieved by injection. Intravail® has also been successfully applied to buccal, oral, and rectal administration of both small molecule and peptidic drugs. Our patented ProTek® technology allows creation of proprietary, easily manufacturable, and stable aqueous or lyophilized dosage forms that maintain the integrity and physiological activity of many protein and peptide therapeutics. ProTek® technology is applicable to injectable, intranasal, and other dosage forms. For more information about Aegis, please visit the Aegis website at: www.aegisthera.com.